Clinical Trial Update: Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating immunotherapy with isatuximab and iberdomide for high-risk smoldering multiple myeloma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• SARCLISA (isatuximab)
• iberdomide (iberdomide)

Snippet

Sponsor: University College, London | Conditions: Smouldering Myeloma | Phase 2 | Status: RECRUITING